Overview

6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder

Status:
Terminated
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This is a 6-week study treatment to evaluate the safety and effectiveness of AZD2066 in patients with major depressive disorder.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Duloxetine Hydrochloride